Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.
Financialcontent
Original source
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Envisagenics today announced a multi-year research collaboration and option agreement with Boehringer Ingelheim to validate selected tumor-specific targets for the development of first-in-class precision therapies for people living with solid tumors. Envisagenics has pioneered an artificial intelligence (AI)-powered approach that is transforming alternative RNA splicing into a new frontier for drug discovery.
Adventist Health Bakersfield is first in Kern County to use Noah Medical's next-generation, robotic-assisted bronchoscopy for earlier lung cancer diagnosis
AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company's investigational new drug (IND) application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy. Patient screening is expected to begin by the first quarter of 2027.
-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- -- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO)
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer